NL-OMON37535已完成不适用
dabigatran and rivaroxaban: prediction of anticoagulant effect - Thrombin predict
Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* Men and women aged 18 to 80 years newly diagnosed with non valvular AF ;* Signed written consent to take part in the study
排除标准
- •* Previous history of thrombotic or major bleeding event;* Known to have prothrombotic risk factors;* Use of oral anticoagulants;* Creatinine clearance < 30 ml/min;* Heart valve problems
研究者
相似试验
进行中（未招募）
不适用
dabigatran and rivaroxaban: prediction of anticoagulant effectEUCTR2012-002263-96-NLMUMC
招募中
4 期
Efficacy and safety of RivaroXaban and DAbigatran versus AcenocouMarol in Cerebral Venous ThrombosisNervous System DiseasesPACTR202202477162480Hasan II University Hospital of Fez60
已完成
4 期
A comparison of Dabigatran, Enoxaparin and Rivaroxaban for venous thromboembolism prophylaxisCondition 1: Deep vein thromboembolism. Condition 2: Malignant neoplasm of lower respiratory tract.Acute embolism and thrombosis of deep veins of lower extremityMalignant neoplasm of lower respiratory tract, part unspecifiedI82.4C39.9IRCT20200407046984N1Semnan University of Medical Sciences57
进行中（未招募）
1 期
ew medication for the prophylaxis of thrombosis in patients with mechanical heart supportpatients with implanted left ventricular assist deviceMedDRA version: 13.1Level: LLTClassification code 10052374Term: Left ventricular assist device insertionSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2010-024534-38-ATMedizinische Universität Wien, Abteilung für Herzchirurgie30
尚未招募
3 期
Assessment of the effect of rivaroxaban on sudden sensorineural hearing lossIRCT20200708048051N1Rasht University of Medical Sciences140